Skip to Main Content
Table 1—

Demographics and results

Baseline
3 months
CHMGComparisonPCHMGComparisonP
n 24 23 NS    
Age (years) 45.8 ± 13.2 44.3 ± 13.4 0.703    
Duration (years) 27.2 ± 16.6 24.0 ± 15.8 0.513    
Sex (male/female) 11/13 10/13 0.871    
BMI (kg/m226.1 ± 4.1 26.9 ± 4.8 0.565    
Treatment       
    MDI 18 16 0.677    
    CSII 0.677    
A1C (%) 7.43 ± 1.0* 7.39 ± 1.0 0.896 7.06 ± 0.8* 7.73 ± 1.4 0.039 
Target A1C       
    <7.5% 14 of 24 13 of 23 0.900 20 of 24 12 of 23 0.023 
    <7.0% 7 of 24 6 of 23 0.814 12 of 24 6 of 23 0.211 
    <6.5% 4 of 24 4 of 23 1.000 4 of 24 3 of 23 1.000 
Insulin dose 51.9 ± 31.4 45.7 ± 28.6 0.413 50.1 ± 31.4 49.0 ± 33.4 0.310 
Glucose target ranges (%)       
    WTR 42.6 ± 19.5 NA NA 49.1 ± 16.7 NA 0.0353§ 
    ATR 53.2 ± 20.4 NA NA 47.6 ± 17.0 NA 0.0355§ 
    BTR 4.2 ± 3.5 NA NA 3.4 ± 6.7 NA 0.638§ 
Baseline
3 months
CHMGComparisonPCHMGComparisonP
n 24 23 NS    
Age (years) 45.8 ± 13.2 44.3 ± 13.4 0.703    
Duration (years) 27.2 ± 16.6 24.0 ± 15.8 0.513    
Sex (male/female) 11/13 10/13 0.871    
BMI (kg/m226.1 ± 4.1 26.9 ± 4.8 0.565    
Treatment       
    MDI 18 16 0.677    
    CSII 0.677    
A1C (%) 7.43 ± 1.0* 7.39 ± 1.0 0.896 7.06 ± 0.8* 7.73 ± 1.4 0.039 
Target A1C       
    <7.5% 14 of 24 13 of 23 0.900 20 of 24 12 of 23 0.023 
    <7.0% 7 of 24 6 of 23 0.814 12 of 24 6 of 23 0.211 
    <6.5% 4 of 24 4 of 23 1.000 4 of 24 3 of 23 1.000 
Insulin dose 51.9 ± 31.4 45.7 ± 28.6 0.413 50.1 ± 31.4 49.0 ± 33.4 0.310 
Glucose target ranges (%)       
    WTR 42.6 ± 19.5 NA NA 49.1 ± 16.7 NA 0.0353§ 
    ATR 53.2 ± 20.4 NA NA 47.6 ± 17.0 NA 0.0355§ 
    BTR 4.2 ± 3.5 NA NA 3.4 ± 6.7 NA 0.638§ 

Data are means ± SD or n unless otherwise indicated.

*

There was a significant decrease (P = 0.047) in A1C in the CHMG group from baseline to 3 months.

There was no significant change in total insulin dose in the CHMG or comparison group from baseline to 3 months.

WTR glycemia was defined as 60–150 mg/dl (3.3–8.3 mmol/l).

§

These P values represent differences in glucose target ranges from baseline to 3 months in the CHMG group using mixed-model repeated-measures analysis. CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection; NA, not applicable; NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal